Why evidence maturity matters more than online momentum

Key takeaways

Across our directory, the three compounds with the most vendors selling them all rate "very low" on evidence.
Semaglutide has the strongest evidence of any peptide we track and the fewest research vendors listing it.
Rank evidence by maturity: regulatory status, the strongest human study, replication, then limits.
A mechanism that explains why something might work is not proof that it does.

The most-sold peptides have the least evidence

We track two things separately: how strong the evidence is for a compound, and how many vendors are selling it.

When you put those two lists side by side, the pattern is uncomfortable.

Compound	Vendors listing it	Our evidence rating	Regulatory status
BPC-157	22	Very low	Not FDA approved
GHK-Cu	22	Very low	Not FDA approved
MOTS-c	22	Very low	Not FDA approved
Ipamorelin	20	Low	Not FDA approved
Semaglutide	2	High	FDA approved

Vendor counts from our price market, checked 25 July 2026. Evidence ratings from the research directory.

The three compounds with the most sellers are the three with the weakest evidence. The one with the strongest evidence behind it has the fewest.

That isn't a coincidence, and it isn't a conspiracy either. It's just what happens when a market is free to sell whatever people are asking about.

Approved drugs sit inside a system of prescriptions, pharmacies, and liability. Compounds that were never approved don't, so they're easier to sell and easier to talk about.

They're also easier to study badly. Peptides are a broad chemical class rather than a therapeutic category, so "peptide research" covers everything from Phase 3 trials to cell-culture work.³

Popularity measures how easy something is to sell. It has never measured whether it works.

Why does a compound get popular anyway?

Usually because the story is good.

The biology sounds elegant, and a mechanism you can picture in your head feels more convincing than one you can't. Early results look striking in a chart, especially before anyone tries to replicate them.

Then a community settles on the same few anecdotes and repeats them until they feel like consensus.

None of that tells you whether a treatment improves an outcome that matters, for whom, or at what cost in side effects.

The four questions, in order

Evidence maturity asks a smaller and harder set of questions than "does it work." Ask them in this order, because a good answer to a later question can't rescue a bad answer to an earlier one.

1. What's the regulatory status, exactly?

Not "is it approved somewhere," but approved for this molecule, this formulation, and this use.¹

Approval is narrow by design. Tesamorelin is FDA-approved, but for HIV-associated lipodystrophy, which tells you very little about any other use someone might suggest for it.

2. What's the strongest human study, and what did it measure?

There's a large gap between a study that moved a blood marker and one that showed people got better.²

A marker is a stand-in for an outcome. Sometimes the stand-in holds up, and often it doesn't.

3. Has anyone reproduced it?

One striking result is a reason to keep looking. It isn't a conclusion.

A single unreplicated finding and a consistent body of work are different kinds of thing, even when the headline number is identical.

4. What are the limits?

How long did the study run, how many people were in it, and how many dropped out before the end? What were the side effects, and who funded the work?

Dropouts matter more than people expect. If a third of participants quit, the results describe the two-thirds who could tolerate it.

Where mechanism papers fit

A paper explaining how a compound might work is not evidence that it does.

This is the single most common substitution in peptide marketing. A plausible mechanism gets presented with the confidence of a clinical result, and the two are nowhere near the same thing.

Mechanism earns more research. It doesn't yet earn your trust.

For most of the compounds in the table above, mechanism research is genuinely all there is. That's not a scandal. It only becomes one when a seller describes it as something else.

What this changes in practice

Early science still counts. It just has a different job.

It justifies curiosity, and it justifies funding the next study. What it can't do is support a real decision about your health, because it hasn't answered the questions a decision depends on.

Mature evidence is what supports a conversation about benefits, tradeoffs, and alternatives.

The mistake is letting a striking early finding borrow the authority of a finished one.

We keep these layers apart on every profile in the research directory, so a promising preclinical result can't quietly inherit the credibility of an unrelated approval. If you want the vendor-side version of this test, we've written how to evaluate a peptide vendor.

And if you're new to the topic, start with what peptides actually are.

Frequently asked questions

Does a peptide being widely sold mean it works?

No, and in our own data the relationship runs the other way. The three compounds stocked by the most vendors in our price market all sit at the bottom of our evidence ratings, while the compound with the strongest evidence is listed by only two research vendors.

What counts as strong evidence for a peptide?

A randomized controlled trial in humans, measuring an outcome that matters to a patient rather than a lab marker, at enough size and duration to detect both benefits and harms, and reproduced by an independent group.

Is a mechanism study evidence that something works?

No. A mechanism study explains why a compound might plausibly work. It justifies further research. It does not establish that the effect happens in people, or that it is large enough to matter.